close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

6.985 +0.715 (+11.40%)
Streaming Delayed Price Updated: 2:10 PM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 245,503
Open 6.580
Bid (Size) 6.920 (100)
Ask (Size) 7.050 (500)
Prev. Close 6.270
Today's Range 6.351 - 7.100
52wk Range 2.070 - 38.25
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in Multiple Sclerosis Imaging Study
Via Investor Brand Network
News headline image
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
Promising Early Data Strengthens Potential of Novel PET Technology to Advance Development of Lucid-MS for Multiple Sclerosis 
From Quantum BioPharma
Via GlobeNewswire

Performance

YTD
-0.4%
-0.4%
1 Month
+123.9%
+123.9%
3 Month
+88.3%
+88.3%
6 Month
-3.1%
-3.1%
1 Year
-43.0%
-43.0%

More News

Read More
News headline image
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
From Quantum BioPharma
Via GlobeNewswire
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
From Quantum BioPharma
Via GlobeNewswire
Friday's after hours session: top gainers and losers ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis
From Quantum BioPharma
Via GlobeNewswire
These stocks are moving in today's session ↗
Via Chartmill
Top movers in Tuesday's session ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd
From Quantum BioPharma
Via GlobeNewswire
Which stocks have an unusual volume on Friday? ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM
From Pomerantz LLP
Via GlobeNewswire
News headline image
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM
From Pomerantz LLP
Via GlobeNewswire
News headline image
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM
From Pomerantz LLP
Via GlobeNewswire
News headline image
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM
From Pomerantz LLP
Via GlobeNewswire
News headline image
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM
From Pomerantz LLP
Via GlobeNewswire
News headline image
QNTM DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026
Via NewMediaWire
Topics Law Enforcement Lawsuit
News headline image
QNTM DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026
Via TheNewswire.com
Topics Law Enforcement Lawsuit

Frequently Asked Questions

Is Quantum Biopharma Ltd. - Class B Subordinate Voting Shares publicly traded?
Yes, Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is publicly traded.
What exchange does Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trade on?
Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Quantum Biopharma Ltd. - Class B Subordinate Voting Shares?
The ticker symbol for Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is QNTM on the Nasdaq Stock Market
What is the current price of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares?
The current price of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is 6.985
When was Quantum Biopharma Ltd. - Class B Subordinate Voting Shares last traded?
The last trade of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares was at 05/19/26 02:10 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today